Ankyrin 3 Antibody (2A8) [DyLight 650]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-05528C
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human, Rat
Applications
Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot
Label
DyLight 650 (Excitation = 652 nm, Emission = 672 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # 2A8
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
The C-terminal 398 amino acids of human Ankyrin 3 expressed in and purified from E. coli.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for Ankyrin 3 Antibody (2A8) [DyLight 650]
Application
Recommended Usage
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Ankyrin 3
Alternate Names
ankyrin G, Ankyrin G119, ankyrin-3, ankyrin-G, Node Of Ranvier
Gene Symbol
ANK3
Additional Ankyrin 3 Products
Product Documents for Ankyrin 3 Antibody (2A8) [DyLight 650]
Product Specific Notices for Ankyrin 3 Antibody (2A8) [DyLight 650]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...